Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Eyevensys is a private, clinical-stage biotechnology company dedicated to developing and commercializing innovative, non-viral gene therapies for ophthalmic diseases. Its core technology, the Electro-سونoporation System (ESS), allows for the safe and efficient delivery of DNA plasmids encoding therapeutic proteins into the ciliary muscle of the eye. This approach aims to provide sustained therapeutic effects with a single administration, potentially transforming treatments for conditions like Uveitis, Retinitis Pigmentosa, Age-related Macular Degeneration (AMD), and other eye diseases.
The Paris headquarters serves as the company's main operational hub, housing its core research and development laboratories, clinical development teams, and corporate functions.
Being located within a major hospital campus (Hôpital St Joseph) provides a unique environment that bridges research with clinical application. The facilities are equipped for advanced gene therapy research and ophthalmological studies.
Eyevensys fosters a highly specialized, research-intensive work culture focused on scientific breakthroughs in gene therapy. The team environment is collaborative, driven by a shared mission to address unmet needs in ophthalmic diseases. Given its biotech nature, it likely involves agile processes and a strong emphasis on data-driven decision-making.
The strategic location in Paris, a key European center for biotechnology and pharmaceutical innovation, allows Eyevensys access to top scientific talent, research collaborations, and a supportive ecosystem for life sciences.
While its primary research and corporate functions are centralized at its Paris headquarters, Eyevensys maintains a global outlook. It conducts clinical trials across multiple international sites, including in Europe and North America, and collaborates with a global network of researchers and institutions. Its U.S. subsidiary supports operations and engagement within the significant North American market.
Bâtiment G, Hôpital St Joseph, 185 rue Raymond Losserand
Paris
Île-de-France
France
Address: c/o Eyevensys Inc., 125 High Street, Oliver Street Tower, 18th Floor, Boston, MA 02110
Facilitates Eyevensys's therapeutic development and commercialization strategy within the key U.S. ophthalmology market by managing local clinical studies and engaging with American stakeholders and investors.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Eyevensys' leadership includes:
Eyevensys has been backed by several prominent investors over the years, including:
Over the last 12 months (from mid-2023 to mid-2024), Eyevensys saw a notable departure in its development leadership. The company continues its clinical advancements under the existing executive team.
Discover the tools Eyevensys uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Eyevensys likely uses a standard professional email format common in the biotechnology industry. The most probable format combines the first initial and last name of the employee.
[first_initial][lastname]@eyevensys.com
Format
rkazandjian@eyevensys.com
Example
75%
Success rate
Eyevensys Website • February 21, 2024
Eyevensys announced its participation in the European Ophthalmology Innovation Summit (EOIS) held in Barcelona, Spain, on February 22, 2024. This engagement allows the company to connect with leaders and innovators in the ophthalmology field and showcase its non-viral gene therapy platform....more
Eyevensys Website • April 19, 2023
Eyevensys announced its presentation of promising preclinical data for EYS611, its gene therapy candidate for lowering intraocular pressure in glaucoma, at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The data highlighted the potential of EYS611 as a novel, long-lasting treatment for glaucoma patients....more
PR Newswire / Eyevensys Website • January 17, 2023
Eyevensys announced the appointment of Dr. Raffy Kazandjian as its new Chief Executive Officer, succeeding Dr. Patricia Zilliox. Dr. Kazandjian brings over 20 years of experience in ophthalmology and biopharmaceutical leadership to steer Eyevensys through its next phase of clinical development and strategic growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Eyevensys, are just a search away.